176 related articles for article (PubMed ID: 15804207)
1. Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings.
Mauskopf JA; Paramore C; Lee WC; Snyder EH
J Manag Care Pharm; 2005 Apr; 11(3):231-51. PubMed ID: 15804207
[TBL] [Abstract][Full Text] [Related]
2. Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer's disease.
Suh DC; Thomas SK; Valiyeva E; Arcona S; Vo L
Drugs Aging; 2005; 22(8):695-707. PubMed ID: 16060719
[TBL] [Abstract][Full Text] [Related]
3. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.
Mucha L; Shaohung S; Cuffel B; McRae T; Mark TL; Del Valle M
J Manag Care Pharm; 2008 Jun; 14(5):451-61. PubMed ID: 18597574
[TBL] [Abstract][Full Text] [Related]
4. Impact of rivastigmine use on the risk of nursing home placement in a US sample.
Beusterien KM; Thomas SK; Gause D; Kimel M; Arcona S; Mirski D
CNS Drugs; 2004; 18(15):1143-8. PubMed ID: 15581384
[TBL] [Abstract][Full Text] [Related]
5. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.
Dybicz SB; Keohane DJ; Erwin WG; McRae T; Shah SN
Am J Geriatr Pharmacother; 2006 Jun; 4(2):154-60. PubMed ID: 16860262
[TBL] [Abstract][Full Text] [Related]
6. Use of antipsychotic drugs in patients with Alzheimer's disease treated with rivastigmine versus donepezil: a retrospective, parallel-cohort, hypothesis-generating study.
Scharre DW; Vekeman F; Lefebvre P; Mody-Patel N; Kahler KH; Duh MS
Drugs Aging; 2010 Nov; 27(11):903-13. PubMed ID: 20964464
[TBL] [Abstract][Full Text] [Related]
7. BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.
Chianella C; Gragnaniello D; Maisano Delser P; Visentini MF; Sette E; Tola MR; Barbujani G; Fuselli S
Eur J Clin Pharmacol; 2011 Nov; 67(11):1147-57. PubMed ID: 21630031
[TBL] [Abstract][Full Text] [Related]
8. Anticholinesterase duration in the Australian veteran population.
Gadzhanova S; Roughead L; Mackson J
Aust N Z J Psychiatry; 2010 May; 44(5):469-74. PubMed ID: 20397790
[TBL] [Abstract][Full Text] [Related]
9. Patient adherence to transdermal rivastigmine after switching from oral donepezil: a retrospective claims database study.
Tian H; Abouzaid S; Chen W; Kahler KH; Kim E
Alzheimer Dis Assoc Disord; 2013; 27(2):182-6. PubMed ID: 22892648
[TBL] [Abstract][Full Text] [Related]
10. [Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine].
Sicras-Mainar A; Vergara J; Leon-Colombo T; Febrer L; Rejas-Gutierrez J
Rev Neurol; 2006 Oct 16-31; 43(8):449-53. PubMed ID: 17033976
[TBL] [Abstract][Full Text] [Related]
11. Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology.
Touchon J; Bergman H; Bullock R; Rapatz G; Nagel J; Lane R
Curr Med Res Opin; 2006 Jan; 22(1):49-59. PubMed ID: 16393430
[TBL] [Abstract][Full Text] [Related]
12. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
[TBL] [Abstract][Full Text] [Related]
13. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
López-Pousa S; Turon-Estrada A; Garre-Olmo J; Pericot-Nierga I; Lozano-Gallego M; Vilalta-Franch M; Hernández-Ferràndiz M; Morante-Muñoz V; Isern-Vila A; Gelada-Batlle E; Majó-Llopart J
Dement Geriatr Cogn Disord; 2005; 19(4):189-95. PubMed ID: 15677866
[TBL] [Abstract][Full Text] [Related]
14. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
Bullock R; Touchon J; Bergman H; Gambina G; He Y; Rapatz G; Nagel J; Lane R
Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542
[TBL] [Abstract][Full Text] [Related]
15. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.
Santoro A; Siviero P; Minicuci N; Bellavista E; Mishto M; Olivieri F; Marchegiani F; Chiamenti AM; Benussi L; Ghidoni R; Nacmias B; Bagnoli S; Ginestroni A; Scarpino O; Feraco E; Gianni W; Cruciani G; Paganelli R; Di Iorio A; Scognamiglio M; Grimaldi LM; Gabelli C; Sorbi S; Binetti G; Crepaldi G; Franceschi C
CNS Drugs; 2010 Feb; 24(2):163-76. PubMed ID: 20088621
[TBL] [Abstract][Full Text] [Related]
16. [Drug-cholinesterase-inhibitors persistence patterns in treated patients with dementia of Alzheimer type: retrospective comparative analysis of donepezil, rivastigmine and galantamine].
Sicras A; Rejas-Gutiérrez J
Rev Neurol; 2004 Aug 16-31; 39(4):312-6. PubMed ID: 15340887
[TBL] [Abstract][Full Text] [Related]
17. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.
Wolfson C; Oremus M; Shukla V; Momoli F; Demers L; Perrault A; Moride Y
Clin Ther; 2002 Jun; 24(6):862-86; discussion 837. PubMed ID: 12117079
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.
Auriacombe S; Pere JJ; Loria-Kanza Y; Vellas B
Curr Med Res Opin; 2002; 18(3):129-38. PubMed ID: 12094822
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of treated patients with Alzheimer's disease: current trends and COVID-19 impact.
Olazarán J; Carnero-Pardo C; Fortea J; Sánchez-Juan P; García-Ribas G; Viñuela F; Martínez-Lage P; Boada M
Alzheimers Res Ther; 2023 Aug; 15(1):130. PubMed ID: 37537656
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence.
Lockhart IA; Mitchell SA; Kelly S
Dement Geriatr Cogn Disord; 2009; 28(5):389-403. PubMed ID: 19893314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
